American CryoStem Marks Major Global Expansion Milestone: Receives First International Shipment of Adipose Tissue for Processin
23 Avril 2013 - 4:45PM
American CryoStem Corporation (OTCQB:CRYO), a
leading strategic developer, marketer and global licensor of
patented adipose tissue-based cellular technologies for the
Regenerative and Personalized Medicine industries, today announced
receipt of its first commercial international shipment of adipose
tissue for processing and long term cryo-storage.
The master sample was shipped to the Company by BALS
(Biomedical and Life Sciences) Institute (BALS), a Hong
Kong-based regenerative medicine company and client of
Personal Cell Sciences Corp. (PCS), the developer
of U-Autologous™ skin care products and formulations. The product
uses an individual's own adult stem cells to create and supply that
individual with his or her own personalized anti-aging skin care
line.
As part of the previously announced contract manufacturing
arrangement between American CryoStem and PCS, American CryoStem is
responsible for clinically testing, processing, culturing and
storing samples shipped from PCS clients to create Autokine-CM™,
the key ingredient in the U-Autologous formulation. BALS
Institute has teamed with PCS to ensure the people in Greater China
gain access to safe, quality and effective life science
technologies through partnerships with leading international
corporations.
"American CryoStem has committed extensive resources to
establishing and perfecting our international shipping
methodologies and protocols, ensuring that our processes meet the
highest possible standards of regulatory compliance for shipment of
biologic materials," stated John Arnone, Chairman and CEO of
American CryoStem. "As a result, our FDA registered laboratory
and cryo-storage facilities in New Jersey are now able to send and
receive viable tissue samples to and from clients globally."
Continuing, Arnone added, "The receipt of our first
international shipment from BALS Institute marks a very important
milestone in our Company's commercial development and triggers what
we expect will be rapid global expansion of our proprietary
platform for clinical processing and commercial bio-banking of
adipose tissue."
Mathew Fan, Director of Marketing and Corporate Development for
BALS Institute, stated, "We are committed to providing our clients
with the most advanced life science treatments and products from
around the globe. Working in close collaboration with leading
world class companies, such as American CryoStem and Personal Cell
Sciences, provides great comfort to our clients, knowing that their
stem cells are safely processed, tested and stored in a United
States facility for their future use."
About BALS Institute
Based in Hong Kong, BALS (Biomedical and Life Sciences)
Institute, a wholly owned subsidiary of the Hong Kong-listed
company HK Life Science and Technology Group Limited, is a
healthcare operational platform providing medical professionals in
China access to the latest developments in life science and
biomedical technology available in the world today. For more
information, please go to
www.bals-institute.com.
About Personal Cell Sciences Corp. (PCS)
Personal Cell Sciences Corp. (PCS) is a privately held Life
Sciences company dedicated to the development and distribution of
personalized Adipose Derived Stem Cell-based anti-aging, topical
skin care products formulated using an individual's own stem
cells. PCS not only produces unique skin care products,
branded under its U Autologous™ skin care line, but it also helps
prepare individuals for the future of Regenerative Medicine by
cryogenically storing a clinical grade sample of an
individual's adult stem cells through its affiliation with American
CryoStem Corporation. For more information, go to
www.personalcellsciences.com.
About American CryoStem Corporation
A pioneer in the fields of Regenerative and Personalized
Medicine, American CryoStem is a developer, marketer and global
licensor of patented adipose tissue-based cellular technologies and
related proprietary services with a focus on clinical processing,
commercial bio-banking and application development for adipose
(fat) tissue and autologous adipose-derived regenerative cells
(ADRCs). The Company maintains a strategic portfolio of
intellectual property and patent applications that form its Adipose
Tissue Processing Platform, which supports and promotes a growing
pipeline of biologic products and processes, clinical services and
international licensing opportunities. Through its ACS
Laboratories division, the Company operates an FDA registered, cGMP
compliant human tissue processing, cryo-storage, cell culture and
differentiation media development facility in Mount Laurel, New
Jersey. For more information, please visit
www.americancryostem.com and
www.acslaboratories.com.
This press release may contain forward-looking statements,
including information about management's view of American CryoStem
Corporation's ("the Company") future expectations, plans and
prospects. In particular, when used in the preceding
discussion, the words "believes," "expects," "intends," "plans,"
"anticipates," or "may," and similar conditional expressions are
intended to identify forward-looking statements. Any
statements made in this press release other than those of
historical fact, about an action, event or development, are
forward-looking statements. These statements involve known and
unknown risks, uncertainties and other factors, which may cause the
results of the Company, its subsidiaries and concepts to be
materially different than those expressed or implied in such
statements. Unknown or unpredictable factors also could have
material adverse effects on the Company's future results. The
forward-looking statements included in this press release are made
only as of the date hereof. The Company cannot guarantee
future results, levels of activity, performance or
achievements. Accordingly, you should not place undue reliance
on these forward-looking statements. Finally, the Company
undertakes no obligation to update these statements after the date
of this release, except as required by law, and also takes no
obligation to update or correct information prepared by third
parties that are not paid for by American CryoStem Corporation.
CONTACT: Hanover|Elite
Kathy Addison or Dodi Handy
407-585-1080 or via email at CRYO@hanoverelite.com
American Cryostem (CE) (USOTC:CRYO)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
American Cryostem (CE) (USOTC:CRYO)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024